Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTH for Pediatric Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
NCT02132195Phase 3Completed
- Sponsor
- Emory University
- Start
- May 2014
- Primary completion
- Jan 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of corticotropin in nephrotic syndrome (3 arms), sponsored by Emory University. Primary endpoints: Number of Participants Experienced a Relapse of Nephrotic Syndrome at 6 months, Proportion of Relapse-Free Patients During First and Second 6 Months of ACTH at 12 months and 1 more. Started May 2014; status: completed.
02
Drugs
corticotropin
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT02132195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02132195.